These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 36308553)

  • 41. Bioinformatic analysis revealing mitotic spindle assembly regulated NDC80 and MAD2L1 as prognostic biomarkers in non-small cell lung cancer development.
    Wei R; Wang Z; Zhang Y; Wang B; Shen N; E L; Li X; Shang L; Shang Y; Yan W; Zhang X; Ma W; Wang C
    BMC Med Genomics; 2020 Aug; 13(1):112. PubMed ID: 32795325
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A Novel Immune-Related Seventeen-Gene Signature for Predicting Early Stage Lung Squamous Cell Carcinoma Prognosis.
    Fan T; Lu Z; Liu Y; Wang L; Tian H; Zheng Y; Zheng B; Xue L; Tan F; Xue Q; Gao S; Li C; He J
    Front Immunol; 2021; 12():665407. PubMed ID: 34177903
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Integrating bulk-RNA sequencing and single-cell sequencing analyses to characterize adenosine-enriched tumor microenvironment landscape and develop an adenosine-related prognostic signature predicting immunotherapy in lung adenocarcinoma.
    Han T; Wu J; Liu Y; Zhou J; Miao R; Guo J; Xu Z; Xing Y; Bai Y; Hu D
    Funct Integr Genomics; 2024 Jan; 24(1):19. PubMed ID: 38265702
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comprehensive analysis of the immunogenic cell death-related signature for predicting prognosis and immunotherapy efficiency in patients with lung adenocarcinoma.
    Cui Y; Li Y; Long S; Xu Y; Liu X; Sun Z; Sun Y; Hu J; Li X
    BMC Med Genomics; 2023 Aug; 16(1):184. PubMed ID: 37553698
    [TBL] [Abstract][Full Text] [Related]  

  • 45. CXCR1 correlates to poor outcomes of EGFR-TKI against advanced non-small cell lung cancer by activating chemokine and JAK/STAT pathway.
    Yang F; Zhang S; Meng Q; Zhou F; Pan B; Liu F; Yu Y
    Pulm Pharmacol Ther; 2021 Apr; 67():102001. PubMed ID: 33582208
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A novel pyroptosis-related lncRNA prognostic signature associated with the immune microenvironment in lung squamous cell carcinoma.
    Zhou W; Zhang W
    BMC Cancer; 2022 Jun; 22(1):694. PubMed ID: 35739504
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Characterization of genomic instability-related genes predicts survival and therapeutic response in lung adenocarcinoma.
    Li S; Wang W; Yu H; Zhang S; Bi W; Sun S; Hong B; Fang Z; Chen X
    BMC Cancer; 2023 Nov; 23(1):1115. PubMed ID: 37974107
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Expression signature, prognosis value and immune characteristics of cathepsin F in non-small cell lung cancer identified by bioinformatics assessment.
    Song L; Wang X; Cheng W; Wu Y; Liu M; Liu R; Zhang S; Xia H; Liu H; Tai X; Zhao H; Li X; Ji F
    BMC Pulm Med; 2021 Dec; 21(1):420. PubMed ID: 34923982
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [CD45RO⁺ Memory T Lymphocytes As A Candidate Marker for Non-small Cell Lung Cancer].
    Tan Q; Li H; Yu M; Tang X; Tan J; Zhang S; Wang J
    Zhongguo Fei Ai Za Zhi; 2021 Apr; 24(4):254-264. PubMed ID: 33910273
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A meta-analysis for CXCR4 as a prognostic marker and potential drug target in non-small cell lung cancer.
    Zhang C; Li J; Han Y; Jiang J
    Drug Des Devel Ther; 2015; 9():3267-78. PubMed ID: 26150700
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prognostic heterogeneity of Ki67 in non-small cell lung cancer: A comprehensive reappraisal on immunohistochemistry and transcriptional data.
    Yang Y; Shao X; Li Z; Zhang L; Yang B; Jin B; Hu X; Qu X; Che X; Liu Y
    J Cell Mol Med; 2024 Jul; 28(14):e18521. PubMed ID: 39021279
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Risk stratification and prognosis prediction based on inflammation-related gene signature in lung squamous carcinoma.
    Zhai W; Chen S; Duan F; Wang J; Zhao Z; Lin Y; Rao B; Wang Y; Zheng L; Long H
    Cancer Med; 2023 Feb; 12(4):4968-4980. PubMed ID: 36056909
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Classification of the immune microenvironment associated with 12 cell death modes and construction of a prognostic model for squamous cell lung cancer.
    Bin Y; Ding P; Liu L; Tong F; Dong X
    J Cancer Res Clin Oncol; 2023 Sep; 149(11):9051-9070. PubMed ID: 37169931
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Exploration of Novel Immunological Terms in Lung Cancer With Large Populations: Implications for Immunotherapy.
    Yao Y; Wang J; Yang F; Gao W
    Front Immunol; 2022; 13():924498. PubMed ID: 35844536
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Integration of multiple key molecules in lung adenocarcinoma identifies prognostic and immunotherapeutic relevant gene signatures.
    Wu Q; Wang L; Wei H; Li B; Yang J; Wang Z; Xu J; Zhou YL; Zhang B
    Int Immunopharmacol; 2020 Jun; 83():106477. PubMed ID: 32278127
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Establishment of non-small-cell lung cancer risk prediction model based on prognosis-associated ADME genes.
    Han K; Wang J; Qian K; Zhao T; Zhang Y
    Biosci Rep; 2021 Oct; 41(10):. PubMed ID: 34522968
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A novel transcriptomic signature associated with lymphovascular invasion predicts clinical outcomes, tumor microenvironment, and therapeutic response in lung adenocarcinoma.
    Huang X; Feng Y; Li Y; Ding H; Huang X; Chen C; Yu Z; Zhang J; Xu X; Ma D; Yu S; Chen C
    Int Immunopharmacol; 2024 Jan; 127():111286. PubMed ID: 38064818
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comprehensive analysis of an immune infiltrate-related competitive endogenous RNA network reveals potential prognostic biomarkers for non-small cell lung cancer.
    Yang CZ; Hu LH; Huang ZY; Deng L; Guo W; Liu S; Xiao X; Yang HX; Lin JT; Sun LL; Lin LZ
    PLoS One; 2021; 16(12):e0260720. PubMed ID: 34855841
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immune subgroup analysis for non-small cell lung cancer may be a good choice for evaluating therapeutic efficacy and prognosis.
    Tian Y; Wang J; Wen Q; Su G; Sun Y
    Aging (Albany NY); 2021 May; 13(9):12691-12709. PubMed ID: 33973529
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Choline metabolism reprogramming mediates an immunosuppressive microenvironment in non-small cell lung cancer (NSCLC) by promoting tumor-associated macrophage functional polarization and endothelial cell proliferation.
    Xiao B; Li G; Gulizeba H; Liu H; Sima X; Zhou T; Huang Y
    J Transl Med; 2024 May; 22(1):442. PubMed ID: 38730286
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.